中信证券股份有限公司（以下简称"中信证券"或"独立财务顾问"）作为 国电南瑞科技股份有限公司（以下简称"国电南瑞"或"公司"）发行股份及支 付现金购买资产并募集配套资金的独立财务顾问，根据《上市公司重大资产重组 管理办法》、《上市公司募集资金监管规则》、《上海证券交易所股票上市规则》 及《上海证券交易所上市公司自律监管指引第 1 号——规范运作》有关规定，对 公司使用部分闲置募集资金进行现金管理及暂时补充流动资金的情况进行核查， 并出具核查意见如下： 一、证券发行上市及募集资金情况 经中国证券监督管理委员会《关于核准国电南瑞科技股份有限公司向南瑞集 团有限公司等发行股份购买资产并募集配套资金的批复》（证监许可[2017]2224 号）核准，公司以非公开发行股份方式向 7 名特定投资者发行了人民币普通股 额为 6,020,040,632.51 元。上述募集资金已于 2018 年 4 月 8 日全部到位。经立 信会计师事务所（特殊普通合伙）对认购资金实收情况进行了审验，并出具了《验 资报告》（信会师报字[2018]第 ZB22786 号）。 二、公司前次使用部分闲置募集资金进行现金管理的情况 为提高募集资金使用效 ...

Group 1 - The stock price of CanSino (688185.SH) closed at 80.87 yuan, reflecting a decline of 4.66% [1] - CanSino was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 13, 2020, with an issuance of 24.8 million shares at a price of 209.71 yuan per share [1] - The company raised a total of 5.201 billion yuan, with a net amount of 4.979 billion yuan after deducting issuance costs, which was 3.979 billion yuan more than the original plan [1] Group 2 - The funds raised were intended for several projects, including the construction of the second phase of the production base, vaccine development, cold chain logistics system, and working capital [1] - The issuance costs for CanSino amounted to 221 million yuan, with underwriting fees accounting for 205 million yuan [2] - CITIC Securities, as the lead underwriter, received an allocation of 496,000 shares, representing 2.00% of the total shares issued, with an investment amount of 104 million yuan [2]

中信证券股份有限公司 根据中国证券监督管理委员会《关于同意江西江南新材料科技股份有限公司 首次公开发行股票注册的批复》（证监许可〔2024〕1805 号）同意注册，并经上 海证券交易所同意，公司首次公开发行人民币普通股（A 股）3,643.63 万股，每 股面值 1 元，每股发行价格为人民币 10.54 元，募集资金总额为人民币 38,403.86 万元，扣除发行费用人民币 5,296.85 万元后，募集资金净额为 33,107.01 万元。 上述募集资金到位情况已经容诚会计师事务所（特殊普通合伙）验证，并于 2025 年 3 月 14 日出具容诚验字[2025]361Z0009 号《验资报告》。 为规范公司募集资金管理和使用，保护公司及投资者权益，公司设立了相关 募集资金专项账户，对募集资金采用了专户储存管理，公司已与保荐机构及募集 资金存储银行签署了募集资金监管协议。 二、募集资金投资项目情况 根据《江西江南新材料科技股份有限公司首次公开发行股票并在主板上市招 股说明书》披露的募集资金使用计划，公司募投项目情况及募集资金使用计划如 下： | | | 单位：万元 | | --- | --- | --- | ...

信德新材发行募集资金总额为236,096.00万元，扣除发行费用后，募集资金净额为216,582.38万元。信德 新材最终募集资金净额比原计划多151582.38万元。信德新材2022年9月1日披露的招股书显示，公司拟 募集资金65,000.00万元，计划用于年产3万吨碳材料产业化升级项目、研发中心项目、补充流动资金。 信德新材发行费用总额为19,513.62万元，其中中信证券获得保荐承销费17,506.74万元。 信德新材于2023年5月24日披露的2022年年度权益分派实施公告显示，公司2022年年度股东大会审议通 过的权益分派预案为以公司2022年12月31日的总股本68,000,000股为基数，向全体股东每10股派发现金 红利人民币10.00元(含税)，共派发现金股利68,000,000.00元(含税)，以资本公积金中的股本溢价向全体 股东每10股转增5股，不送红股，剩余未分配利润结转以后年度分配。权益分派股权登记日为2023年5月 30日，除权除息日为2023年5月31日。 中国经济网北京8月27日讯信德新材（301349）(301349.SZ)今日收报37.47元，跌幅7.44%。 信德新材于20 ...

Group 1 - HeMai Co., Ltd. (688032.SH) experienced a stock price decline of 3.59%, closing at 109.72 yuan, currently in a state of breaking issue [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 20, 2021, with an initial offering price of 557.80 yuan per share and issued 10 million shares [1] - The total funds raised from the initial public offering (IPO) amounted to 5.578 billion yuan, with a net amount of 5.406 billion yuan after deducting issuance costs, exceeding the original plan by 4.848 billion yuan [1] Group 2 - The company announced a dividend plan on May 30, 2022, distributing 30 yuan (pre-tax) for every 10 shares and a bonus of 4 shares, with the ex-dividend date on June 7, 2022 [1] - On June 6, 2023, HeMai Co., Ltd. announced another dividend plan, distributing 53 yuan (pre-tax) for every 10 shares and a bonus of 4.9 shares, with the ex-dividend date on June 13, 2023 [1] - A new dividend plan was announced on June 13, 2024, distributing 36 yuan (pre-tax) for every 10 shares and a bonus of 4.9 shares, with the ex-dividend date on June 19, 2024 [2]

消息面上，近期沪指再度刷新十年高点，沪深交易成交量破三万亿。华西证券指出，市场放量大涨，是 资金情绪正盛的表现。同时，隐含波动率大幅上升，也是投机热度快速上升的信号。往后看，若行情和 隐含波动率加速上涨，行情在短期内或将调整以回归理性；若市场延续"慢牛"格局，同时隐含波动率变 化不大或显著回落，行情波动的时点可能较前一种情况有所延后。 小摩发布研报称，零售投资者中牛市论述正获得越来越多认可，然而证券业估值仍远低于2015年牛市时 的高峰。预计市场上涨趋势将进一步增强，因杠杆水平保持适中，且估值并不苛刻。该行建议投资者通 过券商增加市场风险敞口。 智通财经APP获悉，中资券商股午后跌幅扩大，截至发稿，申万宏源(06806)跌5.44%，报3.3港元；东方 证券(03958)跌5.29%，报7.87港元；中信建投证券(06066)跌4.63%，报14.02港元；中信证券(06030)跌 4.3%，报28.9港元。 ...

Group 1 - Chinese brokerage stocks experienced significant declines in the afternoon, with notable drops including Shenwan Hongyuan down 5.44% to HKD 3.3, Dongfang Securities down 5.29% to HKD 7.87, CITIC Securities down 4.3% to HKD 28.9, and CITIC Jiantou down 4.63% to HKD 14.02 [1] - The recent surge in the Shanghai Composite Index, reaching a ten-year high, and trading volume exceeding CNY 30 trillion indicates strong market sentiment, as noted by Huaxi Securities [1] - The implied volatility has risen significantly, signaling an increase in speculative activity, which may lead to a market adjustment if the trend continues [1] Group 2 - JPMorgan's report highlights that the bullish narrative among retail investors is gaining traction, yet the valuation of the securities industry remains significantly lower than the peak levels seen during the 2015 bull market [1] - The market's upward trend is expected to strengthen further, supported by moderate leverage levels and reasonable valuations, suggesting that investors should increase their market risk exposure through brokerages [1]

在问答环节，公司就各业务板块情况进行了详细解答： -业务收入利润拆分：上半年，因原料价格下降 及下游需求恢复不足，主要产品价格下降，燃料乙醇、淀粉糖、味精等产品销售收入有所下降，但产品 总销量与去年同期基本持平，产销率和开工率较高。通过把握购销节奏、推行系统低成本，上半年毛利 率同比提高1.3个百分点，综合毛利率接近8.5%。其中，燃料乙醇毛利率提高近1个百分点，利润贡献平 稳；淀粉毛利率略降，利润贡献较小；淀粉糖产品毛利率提升约4个百分点，达到12.7%，是利润主要 来源之一，食品原料板块的泰国公司柠檬酸业务利润贡献也较大。生物材料板块的丙交酯产品处于项目 建设期，暂无利润贡献。 -燃料乙醇业务：近两年该业务整体平稳，收入和利润贡献波动不大。市场需 求维持在300 - 350万吨水平，中粮科技燃料乙醇销量平稳且市场占有率高。上半年原料采购均价同比下 降10%左右，销售价格受成本影响下滑。下半年，公司将从原料结构优化和市场需求拓展两方面推动业 务发展。 -淀粉糖业务：成都公司15万吨二期扩建项目进展顺利，已进入收尾阶段，预计九月底投产， 投产后短期内可达满负荷生产，明年进入平稳运行期。江苏太仓项目总投资近十亿 ...

Group 1 - The core viewpoint of the news highlights the trading performance and financial metrics of CITIC Securities, indicating a decline in stock price and specific figures related to margin trading and securities lending [1] - On August 26, CITIC Securities experienced a stock price drop of 1.43%, with a trading volume of 4.46 billion yuan. The margin trading data shows a financing buy-in of 1.049 billion yuan and a net buy of 410 million yuan [1] - The total margin trading balance for CITIC Securities as of August 26 is 14.321 billion yuan, with the financing balance at 14.281 billion yuan, representing 3.70% of the circulating market value, which is below the 30th percentile level over the past year [1] Group 2 - CITIC Securities, established on October 25, 1995, and listed on January 6, 2003, operates in various sectors including securities brokerage, underwriting, asset management, and proprietary trading. The main revenue sources are securities investment (37.69%), brokerage (25.96%), asset management (17.99%), and others (12.05%) [2] - As of March 31, the company reported a net profit of 6.545 billion yuan for the first quarter of 2025, reflecting a year-on-year growth of 32% [2] Group 3 - CITIC Securities has distributed a total of 88.704 billion yuan in dividends since its A-share listing, with 22.009 billion yuan distributed over the past three years [3] - As of March 31, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 12.8514 million shares to 556 million shares, while Huaxia SSE 50 ETF reduced its holdings by 4.7279 million shares to 179 million shares [3]

Core Viewpoint - The initiation of the commercial insurance innovation drug directory adjustment by the National Medical Insurance Administration marks a significant step towards the practical implementation of commercial insurance innovation drug coverage, potentially leading to a revaluation of the healthcare industry [1][2] Group 1: Investment Opportunities - The healthcare industry is expected to experience a "Davis Double Hit," with a restructured valuation system due to the introduction of the commercial insurance innovation drug directory [1] - Three main investment themes are suggested: 1. Innovative drugs and medical devices, which are likely to benefit from increased payment amounts from commercial insurance [1] 2. Comprehensive service providers that enhance insurance companies' product design capabilities and negotiation power for medical products [1][2] 3. Differentiated medical terminals that could open up future growth opportunities and elevate valuation levels [1] Group 2: Market Growth Projections - From 2023 to 2030, the payment amount from commercial health insurance for innovative drugs and medical devices is projected to grow from 7.3 billion to 126.2 billion, with a compound annual growth rate (CAGR) of 50.3% [1] - The introduction of the commercial health insurance directory is expected to increase the usage rate of innovative drugs and medical devices in hospitals, thereby encouraging upstream innovation [1] Group 3: Comprehensive Service Providers - Comprehensive service providers are anticipated to benefit from the commercial insurance innovation drug directory by offering solutions such as clinical value analysis and marketing to insurance companies, as well as consulting and medical inquiry services to insurance clients [2] - Companies like Sipai Health (00314) and Shanghai Pharmaceuticals (601607) with its subsidiary Meixin Health are highlighted as potential beneficiaries [2] Group 4: Multi-layered Payment System - The expansion of commercial health insurance is expected to enhance China's multi-layered payment system, unlocking potential in diverse medical needs that were previously limited [2] - New payment sources are likely to emerge for medical terminals and pharmacies, creating future growth opportunities for medical service companies and the pharmacy sector [2]